Degenerative Mitral Valve DiseaseEXPLORE DMRNCT04666480
Early Feasibility Study of the PLAR Implant and Delivery System to Treat Degenerative Mitral Regurgitation
A study testing Transcatheter mitral valve repair in people with Degenerative Mitral Valve Disease, run by Polares Medical SA at 1 site in United States.
Trial summary
An early feasibility study to evaluate the safety and feasibility of the PLAR Implant and Delivery System to treat severe degenerative mitral regurgitation and to gather preliminary data on its performance thereby providing guidance for future clinical development. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Degenerative Mitral Valve Disease
- What is being tested?
- Transcatheter mitral valve repair
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1 participants
- Where
- 1 siteUnited States
- Study dates
- 30 Apr 2021to 31 Dec 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 18 years of age or older
- Greater than moderate degenerative mitral regurgitation (Grade 3+ or higher) as confirmed by transesophageal echocardiography (TEE) within 90 days prior to study procedure
- Patient must present with an STS Score less than 10%
- High surgical risk for conventional mitral repair or replacement due to morphological criteria (e.g. leaflet or annulus calcifications), but operable, as assessed by the local heart team comprised of a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in treating mitral valve disease and heart failure
- Patient is approved by an independent Patient Eligibility Committee
- New York Heart Association (NYHA) Functional Class III or IV
Show all 9Show fewer
- Patient willing to participate in study and provide signed IRB/EC-approved informed consent
- Treating physician and patient agree that patient is able to return for all required post-procedure follow-up visits
- Women of child-bearing potential have a negative pregnancy test
Who cannot join
- Severe tricuspid regurgitation
- Severe aortic stenosis or insufficiency
- Severe mitral annulus calcification
- Diseased mitral anterior leaflet such as flail / prolapse/ heavy calcification
- Implanted vena cava filter
- Femoral veins with severe angulation and calcification
Show all 31Show fewer
- Contraindication for transesophageal echocardiography (TEE) or MDCT scan.
- Active infection or endocarditis
- Previous mitral valve surgery
- Prior orthotopic heart transplantation
- Pulmonary artery systolic hypertension > 70mmHg
- Evidence of intra-cardiac, inferior vena cava (IVC) or femoral venous thrombus
- Left ventricular ejection fraction (LVEF) < 30%
- Implant or revision of any pacing device < 30 days prior to intervention
- Symptomatic coronary artery disease treated < 30 days prior to study procedure
- Myocardial infarction requiring intervention < 30 days prior to study procedure
- Infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, sarcoidosis), hypertrophic or restrictive cardiomyopathies, and constrictive pericarditis
- Active peptic ulcer or upper gastrointestinal bleeding < 90 days prior to study procedure
- Stroke < 180 days prior to study procedure
- Severe renal insufficiency (creatinine > 3.0 mg/dL) or patient requiring dialysis
- Cardiogenic shock at time of enrolment
- Hemodynamic instability requiring inotropic support or mechanical heart assistance
- Concurrent medical condition with a life expectancy of less than 2 years
- Pregnancy at time of enrolment
- History of bleeding diathesis or coagulopathy or leukopenia (WBC < 3,000 mcL) or acute anemia (Hb < 9 g/dL) or thrombocytopenia (platelets < 50,000 cells mcL)
- Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or clopidogrel, nitinol, tantalum or allergy to contrast agents that cannot be pre-medicated
- Severe dementia or lack of capacity due to conditions that result in either inability to provide informed consent for the trial/procedure, prevent independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up assessments
- Emergency situations
- Company employees or their immediate family members
- Patient is under guardianship
- Patient is participating in another clinical study for which follow-up is currently ongoing
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Early Feasibility EXperience of Posterior Leaflet RestOration to REduce Degenerative Mitral Regurgitation (EXPLORE DMR)
An early feasibility study to evaluate the safety and feasibility of the PLAR Implant and Delivery System to treat severe degenerative mitral regurgitation and to gather preliminary data on its performance thereby providing guidance for future clinical development. The study is a single-arm registry with the last follow-up visit at 5 years post-intervention. The study will enroll up to 10 patients at up to 4 centers in North America.
Read the detailed description
Percutaneous approaches to treat MR promise to provide a sufficient reduction in MR without the risks typically associated with open heart surgery. Furthermore there is an unmet clinical need for patients with severe MR who are refused or denied surgery due to high risk. Percutaneous therapy provides a novel alternative treatment option for these patients with the aim of reducing morbidity and mortality over and above current medical therapy. The Polares Medical PLAR Implant and Delivery System is a catheter-based technology designed to permanently implant a prosthesis using a transvenous / transseptal approach to augment the posterior mitral valve leaflet and improve coapatation of the mitral valve. Approved edge-to-edge repair has already been shown to be a viable alternative for high risk MR patients. However treatment with these devices is limited to specific anatomies and often requires multiple devices which increases clinical risk, adds to procedural time, and can result in residual MR. The PLAR Implant and Delivery System has been designed to overcome and mitigate some of these shortfalls.
- Conditions
- Degenerative Mitral Valve Disease
- Being tested
- Transcatheter mitral valve repair
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Transcatheter mitral valve repairDevice
Also called TMVr
Transvenous approach with a transeptal puncture to place the study device
| Study group | Role | What they receive |
|---|---|---|
| Single-arm study of PLAR Implant and Delivery System | Experimental | All enrolled patients will receive the study device Receives: Device: Transcatheter mitral valve repair |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of all-cause mortality
Primary safety outcome
Measured: 30-days
Incidence of change from baseline to moderate or less mitral regurgitation (Grade 2+ or less) as evaluated by 2D TTE
Primary performance endpoint
Measured: 30-days
Secondary outcomes (5)
Rate of major safety events as defined by MVARC2
Secondary safety endpoint
Measured: 30 days, at 6 and 12 months, and at 2 - 5 years post-intervention
Technical success per MVARC2 definitions
- Absence of procedure mortality
- Successful access, delivery and retrieval of investigation delivery system
- Successful deployment and correct positioning of intended implant(s)
- Freedom from emergency surgery/re-intervention related to device or access procedure
Measured: Technical success is measured at exit from OR
Procedure success per MVARC2 definitions
- Device success
- Absence of major device or procedure-related serious adverse events as below:
- Death
- Stroke
- Life-threatening bleed
- Major vascular complication
- Major cardiac structural complication
- Stage 2 or 3 AKI
- MI or coronary ischemia requiring PCI or CABG
- Shock, heart or respiratory failure requiring IV vasopressors, mechanical intervention or prolonged intubation
- Valve-related dysfunction, migration, thrombosis, or other complication requiring surgery or repeat intervention
Measured: Procedure success is measured at 30 days post-intervention
Device success rate per MVARC2 definitions (all must be present for success)
- Absence of procedure mortality or stroke
- Proper placement and positioning of device
- Freedom from unplanned re-intervention related to device or access procedure
- Continued intended safety and performance of the device:
- No evidence of structural or functional failure
- No device technical failure issues/complications
- MR reduction to moderate or less without stenosis
Measured: Device success is measured at 30 days, at 6 and 12 months, and at 2 - 5 years post-intervention
Patient success rate per MVARC2 definitions (all must be present for success)
- Device success
- Patient returned to pre-procedure setting
- No rehospitalization or reintervention for mitral regurgitation or heart failure
- Functional improvement from baseline by one or more NYHA class
- 6MWT improvement from baseline by 50 metres or more
Measured: Patient success is measured at 12 months post-intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Dec 2020
- Study start30 Apr 2021
- Primary completion31 Dec 2022
- Study completion31 Dec 2022
Why it stopped: Study device refinement in process
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Degenerative Mitral Valve DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Device feasibility
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Single-arm registry
- Masking
- None (open label)
- Enrolment
- 1 participants (actual)
Sponsor and investigators
- Lead sponsor
- Polares Medical SA
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Laura A Brenton, Study director, Polares Medical
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04666480
- Sponsor's protocol ID
- 202001
- Acronym
- EXPLORE DMR
- Status last verified
- Dec 2023
- First submitted
- 1 Dec 2020
- Last updated
- 20 Dec 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No: Clinical trial results will be shared with investigators once study is enrolled and trial data is prepared for presentation at a medical conference or for publication in a medical journal.
Study at a glance
From the registry record, last updated by the sponsor on 20 Dec 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Early Feasibility EXperience of Posterior Leaflet RestOration to REduce Degenerative Mitral Regurgitation (EXPLORE DMR)
- ClinicalTrials.gov ID
- NCT04666480
- Acronym / sponsor ID
- EXPLORE DMR / 202001
- Conditions
- Degenerative Mitral Valve Disease
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Study device refinement in process
- Enrolment
- 1 participants (actual)
- Lead sponsor
- Polares Medical SAIndustry (pharma, biotech, devices)
- Study start
- 30 Apr 2021 (actual)
- Primary completion
- 31 Dec 2022 (actual)
- Study completion
- 31 Dec 2022 (actual)
- First posted
- 14 Dec 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
An early feasibility study to evaluate the safety and feasibility of the PLAR Implant and Delivery System to treat severe degenerative mitral regurgitation and to gather preliminary data on its performance thereby providing guidance for future clinical development. The study is a single-arm registry with the last follow-up visit at 5 years post-intervention. The study will enroll up to 10 patients at up to 4 centers in North America.
Detailed description
Percutaneous approaches to treat MR promise to provide a sufficient reduction in MR without the risks typically associated with open heart surgery. Furthermore there is an unmet clinical need for patients with severe MR who are refused or denied surgery due to high risk. Percutaneous therapy provides a novel alternative treatment option for these patients with the aim of reducing morbidity and mortality over and above current medical therapy. The Polares Medical PLAR Implant and Delivery System is a catheter-based technology designed to permanently implant a prosthesis using a transvenous / transseptal approach to augment the posterior mitral valve leaflet and improve coapatation of the mitral valve. Approved edge-to-edge repair has already been shown to be a viable alternative for high risk MR patients. However treatment with these devices is limited to specific anatomies and often requires multiple devices which increases clinical risk, adds to procedural time, and can result in residual MR. The PLAR Implant and Delivery System has been designed to overcome and mitigate some of these shortfalls.
Study design
- Primary purpose
- Device feasibility
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Single-arm registry
| Arm | Type | Receives |
|---|---|---|
| Single-arm study of PLAR Implant and Delivery System | Experimental | Device: Transcatheter mitral valve repairAll enrolled patients will receive the study device |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- 18 years of age or older
- Greater than moderate degenerative mitral regurgitation (Grade 3+ or higher) as confirmed by transesophageal echocardiography (TEE) within 90 days prior to study procedure
- Patient must present with an STS Score less than 10%
- High surgical risk for conventional mitral repair or replacement due to morphological criteria (e.g. leaflet or annulus calcifications), but operable, as assessed by the local heart team comprised of a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in treating mitral valve disease and heart failure
- Patient is approved by an independent Patient Eligibility Committee
Key exclusion criteria (31 listed)
- Severe tricuspid regurgitation
- Severe aortic stenosis or insufficiency
- Severe mitral annulus calcification
- Diseased mitral anterior leaflet such as flail / prolapse/ heavy calcification
- Implanted vena cava filter
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Transcatheter mitral valve repairAlso: TMVrTransvenous approach with a transeptal puncture to place the study device | Device | Single-arm study of PLAR Implant and Delivery System |
Primary outcome
Incidence of all-cause mortality
Time frame: 30-days
Primary safety outcome
Incidence of change from baseline to moderate or less mitral regurgitation (Grade 2+ or less) as evaluated by 2D TTE
Time frame: 30-days
Primary performance endpoint
5 secondary outcomes
Rate of major safety events as defined by MVARC2
Time frame: 30 days, at 6 and 12 months, and at 2 - 5 years post-intervention
Technical success per MVARC2 definitions
Time frame: Technical success is measured at exit from OR
Procedure success per MVARC2 definitions
Time frame: Procedure success is measured at 30 days post-intervention
Device success rate per MVARC2 definitions (all must be present for success)
Time frame: Device success is measured at 30 days, at 6 and 12 months, and at 2 - 5 years post-intervention
Patient success rate per MVARC2 definitions (all must be present for success)
Time frame: Patient success is measured at 12 months post-intervention
Results and safety
The study was stopped early (reason given: Study device refinement in process). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Dec 2023.
- Individual participant dataSharing planned: No. Clinical trial results will be shared with investigators once study is enrolled and trial data is prepared for presentation at a medical conference or for publication in a medical journal.
Related trials for Degenerative Mitral Valve Disease
Recruiting
TVMR With the INNOVALVE System Trial - Early Feasibility Study
Mitral Valve Regurgitation (Degenerative or Functional)
Not yet recruiting
Anchord Mitral Chordal Repair System - FIH
Mitral Regurgitation
Recruiting
ATLAS (AltaValve) Pivotal Trial
Mitral Regurgitation, Mitral Insufficiency
Active, not recruiting
Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
Mitral Regurgitation, Mitral Insufficiency
Active, not recruiting
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
Degenerative Mitral Valve Disease, Mitral Regurgitation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Laura A Brenton study director
Polares Medical
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Transcatheter mitral valve repair in people with Degenerative Mitral Valve Disease, run by Polares Medical SA at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 31 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 20 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Study device refinement in process). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of all-cause mortality (time frame: 30-days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Dec 2023.